Breaking News Instant updates and real-time market news.

ACAD

Acadia

$15.23

-0.26 (-1.68%)

05:07
08/06/18
08/06
05:07
08/06/18
05:07

Acadia downgraded to Neutral from Overweight at Piper Jaffray

Piper Jaffray analyst Danielle Brill downgraded Acadia Pharmaceuticals to Neutral and cut her firm's price target for the shares to $19 from $61 after taking over coverage of the name. The stock closed Friday down 27c to $15.22. The recent negative headlines related to potential Nuplazid safety issues will continue to weigh on sales and the shares for the foreseeable future, Brill tells investors in a research note. Further, the analyst does not have a high level of conviction for positive data from Acadia's near-term catalysts, namely the Phase 2 major depressive disorder data in September and the Phase 2 negative schizophrenia symptoms readout in the first half of 2019.

  • 08

    Aug

  • 30

    Aug

  • 31

    Aug

ACAD Acadia
$15.23

-0.26 (-1.68%)

11/06/17
LEER
11/06/17
NO CHANGE
Target $35
LEER
Market Perform
Data suggests Acadia pivotal DRP program is high risk, says Leerink
Following full data from Acadia's phase 2 study of pimavanserin in Alzheimer's Disease Psychosis patients at the Clinical Trials on Alzheimer's Disease, Leerink analyst Paul Matteis says his cautious view on the company's phase 3 dementia related psychosis program remains as the statistically significant benefit for pimavanserin seen at the primary endpoint of 6 weeks was in his view helped considerably by a temporary regression in placebo response, this dynamic was also the case in a featured, more severe subgroup, and dementia related psychosis is a chronic condition, and for any new medication a sustained clinical benefit will be important. He reiterates a Market Perform rating and $35 price target on the shares.
04/10/18
JPMS
04/10/18
NO CHANGE
Target $50
JPMS
Overweight
Acadia sees little impact from CNN article, says JPMorgan
JPMorgan analyst Cory Kasimov says Acadia Pharmaceuticals management stressed to him their confidence that yesterday's CNN article would have little impact on Nuplazid's commercial prospects. Kasimov says that while management believes the news changes nothing, he worries "that the already tenuous sentiment around the name could have a difficult time withstanding this latest development." It remains to be seen what extent, if any, the creased scrutiny on the safety profile of Nuplazid negatively impacts the product's commercial outlook, Kasimov tells investors in a research note. He believes Acadia'a Q1 earnings report now has even greater significance. The analyst keeps an Overweight rating on Acadia with a $50 price target.
04/10/18
COWN
04/10/18
NO CHANGE
Target $50
COWN
Outperform
Acadia pimavanserin concerns a reason for caution, says Cowen
Cowen analyst Ritu Baral noted yesterday's media report concerning deaths in the Acadia pimavanserin FAERS log. The analyst said based on conversations with key opinion leaders who have major experience with pimavanserin, she thinks there is unlikely a safety signal. However, she does say the concerns keep her cautious on the stock. Baral maintained her Outperform rating and $50 price target on Acadia shares, which dropped 23% to close at $16.50 yesterday.
04/26/18
JPMS
04/26/18
NO CHANGE
JPMS
Overweight
JPMorgan still sees low risk of Acadia drug being pulled from market
JPMorgan analyst Cory Kasimov continues to see a low, "but not zero," risk of Acadia Pharmaceuticals' Nuplazid being pulled from the market. Yesterday's CNN report is "mostly noise" and "nothing new," Kasimov told investors last night in a research note. The analyst, however, says he can appreciate the impact of the FDA Commissioner indicating he would "take another look" at the drug's safety profile. Kasimov predicates his views on the formal FDA review and the agency's initial statement that Nuplazid's safety profile is consistent with the label, as well as additional commentary he received yesterday from management. The analyst views yesterday's pullback in shares of Acadia as "fundamentally unjustified based on current information." He kept an Overweight rating on the stock. Shares of Acadia are up 5% to $15.95 in early trading.

TODAY'S FREE FLY STORIES

WMT

Walmart

$98.65

-1.24 (-1.24%)

, AMZN

Amazon.com

$1,790.05

27.6 (1.57%)

15:56
03/20/19
03/20
15:56
03/20/19
15:56
Periodicals
Walmart's Chief Technology Officer leaving company, Reuters reports »

Walmart (WMT) Chief…

WMT

Walmart

$98.65

-1.24 (-1.24%)

AMZN

Amazon.com

$1,790.05

27.6 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

  • 16

    May

SCHW

Charles Schwab

$44.70

-1.05 (-2.30%)

15:55
03/20/19
03/20
15:55
03/20/19
15:55
Options
Charles Schwab put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
03/20/19
03/20
15:55
03/20/19
15:55
Conference/Events
William Blair healthcare/biotech analysts to hold a dinner meeting »

Analysts meet with…

APTO

Aptose Biosciences

$2.29

0.15 (7.01%)

15:54
03/20/19
03/20
15:54
03/20/19
15:54
Conference/Events
Aptose Biosciences management to meet with Oppenheimer »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 25

    Mar

JOUT

Johnson Outdoors

$69.11

-0.54 (-0.78%)

15:51
03/20/19
03/20
15:51
03/20/19
15:51
Conference/Events
Johnson Outdoors management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

FB

Facebook

$165.22

3.63 (2.25%)

, SPOT

Spotify

$144.16

2.565 (1.81%)

15:51
03/20/19
03/20
15:51
03/20/19
15:51
On The Fly
#SocialStocks: Facebook downgraded to cap rough week »

Welcome to…

FB

Facebook

$165.22

3.63 (2.25%)

SPOT

Spotify

$144.16

2.565 (1.81%)

AAPL

Apple

$188.13

1.56 (0.84%)

SNAP

Snap

$10.93

0.3 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

WTW

WW

$19.50

-0.34 (-1.71%)

15:50
03/20/19
03/20
15:50
03/20/19
15:50
Conference/Events
WW management to meet with Oppenheimer »

Meeting to be held New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 28

    May

WMT

Walmart

$98.64

-1.25 (-1.25%)

15:49
03/20/19
03/20
15:49
03/20/19
15:49
Periodicals
Breaking Periodicals news story on Walmart »

Walmart CTO leaving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

WIFI

Boingo Wireless

$20.68

-0.25 (-1.19%)

15:41
03/20/19
03/20
15:41
03/20/19
15:41
Conference/Events
Boingo Wireless management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 28

    May

C

Citi

$65.04

-0.59 (-0.90%)

15:40
03/20/19
03/20
15:40
03/20/19
15:40
Periodicals
Citi plans to sell Venezuelan gold placed as collateral, Reuters says »

Citigroup intends to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Apr

  • 16

    Apr

  • 28

    May

  • 13

    Jul

EVER

EverQuote

$7.70

(0.00%)

15:40
03/20/19
03/20
15:40
03/20/19
15:40
Conference/Events
EverQuote management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 28

    Mar

CASY

Casey's General Stores

$127.10

0.55 (0.43%)

15:40
03/20/19
03/20
15:40
03/20/19
15:40
Options
Call spreads and put spreads in Caseys General Stores »

Call spreads and put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Apr

  • 03

    Apr

LRAD

LRAD Corporation

$2.82

-0.03 (-1.05%)

15:39
03/20/19
03/20
15:39
03/20/19
15:39
Conference/Events
LRAD Corporation management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

KAMN

Kaman

$57.82

0.325 (0.57%)

15:38
03/20/19
03/20
15:38
03/20/19
15:38
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

The company's KDG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

PVTL

Pivotal Software

$19.94

-0.02 (-0.10%)

15:36
03/20/19
03/20
15:36
03/20/19
15:36
Options
Calls lead puts 25:1 in Pivotal Software »

Calls lead puts 25:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

SYX

Systemax

$21.53

0.23 (1.08%)

15:35
03/20/19
03/20
15:35
03/20/19
15:35
Conference/Events
Systemax management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 28

    Mar

WSM

Williams-Sonoma

$57.40

0.61 (1.07%)

15:34
03/20/19
03/20
15:34
03/20/19
15:34
Options
Williams Sonoma options imply 10.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

SCS

Steelcase

$15.43

-2.055 (-11.75%)

15:34
03/20/19
03/20
15:34
03/20/19
15:34
Conference/Events
Steelcase management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 25

    Mar

  • 14

    May

  • 24

    Jun

  • 26

    Jun

15:30
03/20/19
03/20
15:30
03/20/19
15:30
General news
Powell on the maturity distribution of the portfolio: »

Powell on the maturity…

VLKAY

Volkswagen

$0.00

(0.00%)

15:25
03/20/19
03/20
15:25
03/20/19
15:25
Periodicals
Volkswagen management not yet aligned on restructuring plans, Reuters says »

Volkswagen's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:20
03/20/19
03/20
15:20
03/20/19
15:20
General news
Powell on the balance sheet: »

Powell on the balance…

15:20
03/20/19
03/20
15:20
03/20/19
15:20
General news
Powell on Brexit »

Powell on Brexit: he hope…

WPM

Wheaton Precious Metals

$23.12

0.385 (1.69%)

15:19
03/20/19
03/20
15:19
03/20/19
15:19
Options
Wheaton Precious Metals options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
03/20/19
03/20
15:17
03/20/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
03/20/19
03/20
15:16
03/20/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.